Clinical Edge Journal Scan

Re-BCS may not be the best strategy in ipsilateral breast tumor recurrence


 

Key clinical point: Repeat breast-conserving surgery (re-BCS) worsened survival outcomes in patients with small ipsilateral breast tumor recurrence (IBTR), especially in those with estrogen receptor-negative (ER−) IBTR and those who omitted radiation after re-BCS.

Major finding: Compared with mastectomy, re-BCS was associated with worse overall survival (OS; hazard ratio [HR] 1.342; 95% CI 1.084-1.663) and breast cancer-specific survival (BCSS; HR 1.454; 95% CI 1.004-2.105). After re-BCS, the omission of radiation worsened OS (overall re-BCS without radiation: HR 1.384; 95% CI 1.110-1.724; and negative IBTR ER re-BCS without radiation: HR 1.972; 95% CI 1.191-3.265, respectively) and BCSS (overall re-BCS without radiation: HR 1.577; 95% CI 1.075-2.314; and negative IBTR ER re-BCS without radiation: HR 2.097; 95% CI 1.053-4.178, respectively).

Study details : Findings are from a population-based cohort study including 3648 patients with small IBTR, of which 22.4% of patients underwent re-BCS and the remaining patients underwent mastectomy.

Disclosures: This study did not report any funding source. The authors declared no conflicts of interest.

Source: Li Y et al. Is repeat breast conservation possible for small ipsilateral breast cancer recurrence? Cancer. 2022 (Sep 20). Doi: 10.1002/cncr.34468

Recommended Reading

Cost paramount when choosing metastatic breast cancer treatment
MDedge Hematology and Oncology
Cancer as a full contact sport
MDedge Hematology and Oncology
Is early-onset cancer an emerging global epidemic?
MDedge Hematology and Oncology
What is known about sexual dysfunction after breast cancer?
MDedge Hematology and Oncology
Reminder that COVID-19 and cancer can be a deadly combo
MDedge Hematology and Oncology
Hair straighteners’ risk too small for docs to advise against their use
MDedge Hematology and Oncology
Switching to fulvestrant + palbociclib benefits ER + HER2− BC patients with rising bESR1mut
MDedge Hematology and Oncology
Metastatic TNBC: Apatinib + vinorelbine shows acceptable efficacy and safety in phase 2
MDedge Hematology and Oncology
HER2+ metastatic BC: Dual blockade with P + T effective and safe in routine clinical practice
MDedge Hematology and Oncology
Differential prognosis of germline BRCA1/2 mutations according to tumor subtypes
MDedge Hematology and Oncology